{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 12 of 169', '12.3.5.4', 'Analysis of other endpoints', '105', '12.3.5.4.1', 'Efficacy over time', '105', '12.3.5.4.2', 'Patient-reported outcomes', '106', '12.3.5.4.3', 'Skin microbiology', '108', '12.3.6 Analysis of maintenance treatment', '108', '12.3.6.1 Analysis of maintenance endpoints', '108', '12.3.6.2 Analysis of other maintenance endpoints', '110', '12.3.6.2.1', 'Time to relapse', '110', '12.3.6.2.2 Continued treatment for non IGA responders', '110', '12.3.6.2.3', 'Supportive maintenance', '110', '12.3.7', 'Analysis of safety', '110', '12.3.7.1', 'Adverse events', '111', '12.3.7.2', 'Vital signs', '111', '12.3.7.3', 'Clinical laboratory evaluation', '112', '12.3.7.4', 'Pharmacokinetics', '112', '12.3.7.5', 'Anti-drug antibodies', '112', '12.3.8 Interim analysis', '113', \"12.3.9 Analysis of data per last subject's Week 52 visit\", '113', '12.3.10 General principles', '113', '12.3.11 Handling of missing values', '114', '13 References', '115', 'Appendix 1: Protocol summary', '119', 'Appendix 2: Definitions of adverse events and serious adverse events', '124', 'Appendix 3: Classification of adverse events', '126', 'Appendix 4: Trial governance considerations', '128', 'Appendix 4A: Regulatory and ethical considerations', '128', 'Appendix 4B: Informed consent process', '128', 'Appendix 4C: Subject and data confidentiality', '129', 'Appendix 4D: Record keeping, quality control, and data handling', '130', 'Appendix 4E: Registration, reporting and publication policy', '134', 'Appendix 4F: Insurance', '135', 'Appendix 4G: Financial disclosure', '136', 'Appendix 4H: Committee structure', '136', 'Appendix 4I: Trial and site closure', '137', 'Appendix 4J: Responsibilities', '138', 'Appendix 5: Hanifin and Rajka (1980) diagnostic criteria for AD', '139', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 13 of 169', 'Appendix 6: Guidance for anaphylaxis diagnosis', '140', 'Appendix 7: Country-specific requirements', '142', 'Appendix 8: Contact list', '146', 'Appendix 9: WHO model prescribing information for classification of topical corticosteroids', '149', 'Appendix 10: Protocol amendment history', '151', 'List of panels', 'Panel 1 Trial design', '17', 'Panel 2 Schedule of trial procedures: screening and initial treatment period', '18', 'Panel 3 Schedule of trial procedures: maintenance treatment period and follow-up', '22', 'Panel 4 Schedule of trial procedures: open-label tralokinumab and follow-up', '25', 'Panel 5 Schedule of trial procedures: short-term extension and follow-up (selected countries)', '28', 'Panel 6 Objectives and endpoints: initial treatment period', '37', 'Panel 7 Objectives and endpoints: maintenance treatment period', '39', 'Panel 8 Identification of investigational medicinal products', '52', 'Panel 9 Overview of schedules of procedures', '65', \"Panel 10 Investigator's Global Assessment\", '68', 'Panel 11 Calculation of the Eczema Area and Severity Index', '69', 'Panel 12 EASI severity score scale and area score scale', '69', 'Panel 13 Central laboratory testing', '77', 'Panel 14 Adverse events of special interest', '87', 'Panel 15 Testing procedure for primary, secondary, and maintenance endpoints', '94', 'Panel 16 Transmission of electronic data', '133', 'Panel 17 Classification of topical corticosteroids', '149', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}